If you are a clinician prescribing Reglan, you may have questions about tardive dyskinesia risk and how to monitor patients. The medical literature has long established that prolonged use of metoclopramide can lead to this movement disorder. This page provides prescribing information and risk management guidance for Washington-based practitioners.
Reglan (metoclopramide) is a medication approved for short-term use in adults with symptomatic gastroesophageal reflux that has not responded to conventional therapy, and for relief of symptoms in adults with acute and recurrent diabetic gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The FDA-approved labeling includes a boxed warning stating that metoclopramide, including Reglan, can cause tardive dyskinesia (TD), a potentially irreversible serious movement disorder (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The risk of developing TD increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is contraindicated in patients with a history of TD, and the labeling instructs clinicians to use Reglan for the shortest duration of treatment and to periodically reassess the need for continued treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with symptomatic, documented gastroesophageal reflux, the maximum duration of Reglan treatment is 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). In patients with diabetic gastroparesis, the labeling advises avoiding a total duration of treatment with metoclopramide products, including Reglan tablets, for longer than 12 weeks, and if longer-term use is unavoidable, to routinely monitor for signs and symptoms of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
Tardive dyskinesia is characterized by involuntary, repetitive movements of the face, tongue, trunk, and/or extremities, and these movements can be disfiguring (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The labeling notes that metoclopramide may suppress or partially suppress the signs of TD and may delay the diagnosis because it can mask the underlying disease process (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The mechanism linking Reglan to TD involves the drug's dopamine receptor-blocking properties, which can lead to supersensitivity of dopamine receptors in the basal ganglia, a brain region involved in motor control. This supersensitivity is thought to contribute to the development of abnormal involuntary movements. The risk is particularly concerning because TD can become permanent even after the drug is discontinued. The adequacy of warnings regarding Reglan and TD is a critical issue. The boxed warning is prominently placed in the prescribing information, but questions may arise about whether prescribers and patients were adequately informed about the risks, especially given that Reglan has been used off-label for longer periods than recommended. The labeling explicitly states that Reglan has not been shown to be safe and effective for the treatment of symptomatic, documented gastroesophageal reflux for longer than 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Additionally, Reglan tablets are not recommended for use in pediatric patients due to the risk of developing TD and other extrapyramidal symptoms, as well as the risk of methemoglobinemia in neonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
For affected patients in Washington, attorney-related considerations involve the statute of limitations, which is the time limit for filing a lawsuit. In Washington, the statute of limitations for personal injury claims, including those related to medication-induced TD, is generally three years from the date the injury was discovered or should have been discovered with reasonable diligence. This timeline is crucial because TD often develops insidiously, and patients may not immediately recognize the connection between their symptoms and Reglan use. The timeline between exposure to Reglan and documented harm can vary widely. Some patients develop TD after only a few months of use, while others may not show symptoms until after years of treatment. The labeling emphasizes that the risk increases with duration of treatment and total cumulative dosage, meaning that longer exposure correlates with higher risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Once TD is diagnosed, it is often irreversible, and the labeling instructs clinicians to immediately discontinue Reglan in patients who develop signs or symptoms of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Patients who have developed TD after using Reglan may seek legal recourse, and an attorney can help evaluate whether the statute of limitations has been met. The key is to determine when the patient knew or should have known that their TD was caused by Reglan. This can be complicated by the fact that TD symptoms may be mistaken for other conditions, and the diagnosis may be delayed. The labeling's warning about metoclopramide potentially masking TD symptoms further complicates the timeline (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). An attorney will also consider whether the prescribing physician provided adequate warnings and whether the patient was monitored appropriately. The FDA-approved labeling clearly states that Reglan should be used for the shortest duration necessary and that the need for continued treatment should be periodically reassessed (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Failure to follow these guidelines may be considered a deviation from the standard of care.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In Washington, the statute of limitations for personal injury claims, including those related to Reglan-induced tardive dyskinesia, is generally three years from the date the injury was discovered or should have been discovered with reasonable diligence. Because TD often develops insidiously, it is important to consult an attorney promptly to determine if your claim is timely.
Yes, Reglan (metoclopramide) carries a boxed warning stating that it can cause tardive dyskinesia, a potentially irreversible serious movement disorder. The risk increases with duration of treatment and total cumulative dosage. Even after discontinuing the drug, TD may become permanent.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Request archival records or inquire about member-exclusive transition and benefit programs.
Individuals with documented archive exposure and a related diagnosis may request an independent, no-cost eligibility review.